You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

~ Buy the MYOVIEW 30ML (technetium tc-99m tetrofosmin kit) Drug Profile, 2024 PDF Report in the Report Store ~

MYOVIEW 30ML Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Myoview 30ml patents expire, and when can generic versions of Myoview 30ml launch?

Myoview 30ml is a drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this drug.

This drug has eight patent family members in seven countries.

The generic ingredient in MYOVIEW 30ML is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.

DrugPatentWatch® Generic Entry Outlook for Myoview 30ml

Myoview 30ml was eligible for patent challenges on February 9, 2000.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 10, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for MYOVIEW 30ML
Drug patent expirations by year for MYOVIEW 30ML
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for MYOVIEW 30ML
Generic Entry Date for MYOVIEW 30ML*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MYOVIEW 30ML

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Astellas Pharma IncPhase 2
GE HealthcarePhase 4

See all MYOVIEW 30ML clinical trials

US Patents and Regulatory Information for MYOVIEW 30ML

MYOVIEW 30ML is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of MYOVIEW 30ML is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting MYOVIEW 30ML

Radiopharmaceutical composition
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare MYOVIEW 30ML technetium tc-99m tetrofosmin kit INJECTABLE;INJECTION 020372-002 Jul 7, 2005 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for MYOVIEW 30ML

When does loss-of-exclusivity occur for MYOVIEW 30ML?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

Patent: 1861170
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 90484
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 49203
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 64328
Estimated Expiration: ⤷  Try a Trial

Patent: 10539222
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 62441
Estimated Expiration: ⤷  Try a Trial

United Kingdom

Patent: 18386
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MYOVIEW 30ML around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0337654 Ligands et leurs complexes avec le technétium-99m (Ligands and cationic complexes thereof with technetium-99m) ⤷  Try a Trial
United Kingdom 0718386 ⤷  Try a Trial
Hong Kong 98097 Ligands and cationic complexes thereof with technetium-99m ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MYOVIEW 30ML

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1178838 300736 Netherlands ⤷  Try a Trial PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.